Boston Scientific Corp. (NYSE: BSX): Credit Suisse on Tuesday upgraded its rating on the company to Buy from Hold citing compelling risk/reward, expectations for an acceleration in EPS growth, and cost reductions.
F5 Networks (NASDAQ: FFIV): Barclays this morning upgraded this rating on the company to Overweight from Equal-weight. The firm lifted its price target on the stock to $125 from $100.
Biogen Idec Inc. (NASDAQ: BIIB): Credit Suisse upgraded its rating on the company to Outperform from Neutral. The firm raised its price target on the company to $126 from $100.
Synovus Financial Corp. (NYSE: SNV): Wunderlich Securities downgraded to Hold from Buy. The firm lowered its price target on the company to $2.50 from $3.50.
Forest Laboratories (NYSE: FRX): Argus upgraded its rating on the company to Buy from Hold.
Full Disclosure: None.